



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: CLARK, Abbot F., et al.

Serial No: 10/658,986 (Conf #6064)

Filed: 10 September 2003

Examiner:

Group Art Unit:

FOR: Methods For Diagnosing Glaucoma And Discovering Anti-Glaucoma Drugs

INFORMATION DISCLOSURE STATEMENT PURSUANT
TO 37 C.F.R. 1.56, 1.97, AND 1.98Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Pursuant to the duty of disclosure under 37 C.F.R. 1.56, 1.97, and 1.98, Applicants submit the patents, articles, and other information referenced in the specification as filed. The references are listed on the attached PTO Form 1449.

Applicants request that the listed patents, articles, and other information be considered during prosecution of this application and that they appear among the "References Cited" on any patent issuing herefrom.

Respectfully submitted,

10 Feb. 2004

Date

By:

Teresa J. Schultz

Registration No. 40,256
817-551-4231Address for Correspondence:
Alcon Research, Ltd.
Attn: Teresa J. Schultz
6201 S. Freeway, Mail Code Q-148
Fort Worth, TX 76134-2099

Attorney Docket No.: 1581 US FA



PTO/SB/08A (04-03)

Approved for use through 04/30/2003: OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known			
		Application Number	10/658,986 (Conf #6064)		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Filing Date	10 September 2003		
		First Named Inventor	CLARK, Abbot F., et al.		
		Art Unit			
		Examiner Name			
Sheet	1	of	3	Attorney Docket Number	1581 US FA

U. S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	A1	US-			
	A2	US-			
	A3	US-			
	A4	US-			
	A5	US-			
	A6	US-			
	A7	US-			
	A8	US-			
	A9	US-			
	A10	US-			
	A11	US-			
	A12	US-			
	A13	US-			
	A14	US-			
	A15	US-			
	A16	US-			
	A17	US-			
	A18	US-			
	A19	US-			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (If known)				
	A20	AU 728438	04/26/2001	Clark et al.		
	A21	WO 96/14411 A1	05/17/1996	University of Callifomia		
	A22	WO 96/33287 A1	10/24/1996	Institut National De La Rec		
	A23	WO 98/24932 A1	06/11/1998	Clark et al.		
	A24					
	A25					

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (04-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/658,986 (Conf #6064)		
	Filing Date		
	10 September 2003		
	First Named Inventor		
	CLARK, Abbot F., et al.		
Art Unit			
Examiner Name			
Sheet	2	of	3
Attorney Docket Number		1581 US FA	

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	B1	Bamberger, et al., The Journal of Clinical Investigation, "Glucocorticoid Receptor β , a Potential endogenous Inhibitor of Glucocorticoid Action in Humans," 95:2435-2441, 1995	
	B2	Caskey, C.T., J.A.M.A., "Molecular Medicine. A Spin-off From the Helix," 269:15, 1986-1992, 1993	
	B3	Clark, A.F. Journal of Glaucoma, "Steroids, Ocular Hypertension, and Glaucoma", 4:354-369, 1995	
	B4	Cummings, Michael R., Human Heredity, Fourth Edition, 1997	
	B5	Encio, et al., Journal of Biological Chemistry, "The Genomic Structure of the Human Glucocorticoid Receptor," 266(11):7182-7188, 1991	
	B6	Giguère et al., "Functional Domains of the Human Glucocorticoid Receptor," Cell, 46:645-652, 1986	
	B7	Hernandez, et al., Invest. Ophthalmol. Vis. Sci., "Glucocorticoid Target Cells in Human Outflow Pathway: Autopsy and Surgical Specimens," 24:1612-1616, 1983	
	B8	Hollenberg et al., "Primary structure and expression of a functional human glucocorticoid receptor cDNA," Nature, 318:635-641, 1985	
	B9	Jorde, et al., Medical Genetics, Second Edition, 1999	
	B10	Leung, et al., "Association of Glucocorticoid Insensitivity with Increased Expression of Glucocorticoid Receptor β ," Journal of Experimental Medicine, 186(9):1567-1574, 1997	

Examiner Signature	Date Considered
-------------------------------	----------------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the Individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/088 (04-03)

Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/658,986 (Conf #6064)
				Filing Date	10 September 2003
				First Named Inventor	CLARK, Abbot F., et al.
				Art Unit	
				Examiner Name	
Sheet	3	of	3	Attorney Docket Number	1581 US FA

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C1	Myers, R.M., et al., "Detection of DNA Variation", Genome Analysis, Birren (eds) 2:287-384, 1998	
	C2	Oakley et al., "Expression and Subcellular Distribution of the β -Isoform of the Human Glucocorticoid Receptor," Endocrinology, 138(11):5028-5038, 1997	
	C3	Oakley, et al., The Journal of Biological Chemistry, "The Human Glucocorticoid Receptor β Isoform," 271:16, 9550-9559, 1996	
	C4	Strachan, et al., Human Molecular Genetics, 367-399, 1996	
	C5	Weinreb, et al., Invest. Ophthalmol. Vis. Sci., "Detection of Glucocorticoid Receptors in Cultured Human Trabecular Cells," 21:3, 403-407, 1981	
	C6	Wordinger, et al., "Effects of Glucocorticoids on the Trabecular Meshwork: Towards a Better Understanding of Glaucoma," Progress in Retinal and Eye Research, 18(5):629-667, 1999	
	C7		
	C8		
	C9		
	C10		

Examiner Signature	Date Considered
-----------------------	--------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.